Breast cancer screening and treatment methods

G - Physics – 01 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

G01N 33/574 (2006.01)

Patent

CA 2668725

A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.

Procédé de sélection de personne atteinte de cancer du sein pour une thérapie à antagoniste du récepteur AT1, qui consiste, (a) à déterminer si le cancer comporte une tumeur qui est ER+ et/ou PR+; et (b) à sélectionner la personne pour cette thérapie uniquement si le cancer est déterminé comme comportant ladite tumeur. On décrit un procédé de traitement de cancer du sein chez une femme qui consiste par ailleurs (c) à lui administrer, si elle répond à la sélection, ledit antagoniste selon un dosage efficace pour réduire la croissance, le pouvoir envahissant et/ou la métastase de la tumeur.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Breast cancer screening and treatment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Breast cancer screening and treatment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer screening and treatment methods will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1841822

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.